Dear Editor,

Acute kidney injury (AKI) carries high mortality and morbidity \[[@CR1], [@CR2]\]. Two studies recently suggested the potential benefit of renin-angiotensin system (RAS) blockers (angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)) after AKI \[[@CR3], [@CR4]\]. The first one reported a lower mortality after 1 year of follow-up in patients receiving an ACEi or ARB after an episode of AKI (KDIGO stages 1 to 3) at ICU discharge (20/109 (18%) vs 153/502 (31%), *p* = 0.001) \[[@CR3]\]. The second one was a retrospective cohort study including adults after an episode of AKI during hospital stay (with 18% only of ICU-patients and only 7% of KDIGO stage 3) \[[@CR4]\]. It concluded that exposure to an RAS blocker within the first 6 months after hospital discharge was associated with a 15% decrease in all-cause mortality (HR, 0.85; 95%CI, 0.81--0.89).

We performed an ancillary of the AKIKI trial \[[@CR5]\], which included 619 ICU patients with severe AKI (KDIGO stage 3) in order to evaluate the potential effect of RAS blockers on long-term mortality.

All patients discharged alive from ICU were included, and their long-term prognosis (2-year all-cause mortality) was assessed according to treatment with ACEi/ARB at ICU discharge using both univariate and multivariate analyses.

Among 348 patients discharged alive from ICU, 45 (12.9%) received an ACEi/ARB at ICU discharge (see Table [1](#Tab1){ref-type="table"} for patient characteristics). Patients without ACEi/ARB were more severe as attested by a higher SAPS 3 (*p* = 0.02) and a higher rate of catecholamine infusion (*p* = 0.008) during AKI. However, 2-year all-cause mortality did not significantly differ between the two groups (12/45 (27%) with ACEi/ARB vs 55/303 (18%) without, *p* = 0.18). Mortality risk was not associated with non-prescription of ACEi/ARB after adjustment for prognostic variables (*p* = 0.21) (Table [2](#Tab2){ref-type="table"}).Table 1Patient characteristicsACEi/ARB +\
(*N* = 45)ACEi/ARB - (*N* = 303)*p*Characteristic at ICU admission Age---years64.4 ± 15.163.1 ± 14.70.6 Male sex---no. (%)32 (71)193 (63)0.3 Weight---kg85.8 ± 23.782.4 ± 20.50.3Main reason for ICU admission---no. (%) Medical37 (82)263 (87) Surgical, emergency5 (11)66 (22) Surgical, scheduled3 (7)19 (6)Serum creatinine before ICU admission92.0 ± 24.783.4 ± 24.00.03Coexisting condition---no. (%) Chronic renal failure6 (13)26 (9)0.3 Hypertension28 (62)152 (50)0.1 Diabetes mellitus3 (7)31 (10)0.67 Congestive heart failure6 (13)17 (6)0.05 Ischemic heart disease8 (18)26 (9)0.05SAPS III at ICU admission63.0 ± 14.068.3 ± 14.30.02Septic shock---no. (%)26 (58)128 (42)0.05Biological characteristics Serum creatinine---µmol/L203.9 (133.1)219.6 (136.9)0.47 Blood urea nitrogen---mmol/L13.0 (8.4)14.4 (9.3)0.34 Serum potassium---mmol/L4.1 (0.8)4.3 (0.9)0.37 Serum bicarbonate---mmol/L19.9 (5.0)18.7 (5.7)0.17Characteristic of ICU stay Physiological support during ICU stay---no. (%)  Invasive mechanical ventilation41 (91)260 (86)0.33  Vasopressor support (epinephrine or norepinephrine)31 (69)257 (85)0.008Number of patients who received RRT---no. (%)28 (62)211 (70)0.32Ventilator duration---median (IQR)5 (5--13)5 (4--10)0.40Vasopressor-free days---median (IQR)3 (2--5)4 (2--7)0.11Length of ICU stay---median (IQR)18 (11--20)15 (8--22)0.35RRT dependence---no. (%) At day 284 (9)27 (9)0.99 At day 601 (2)9 (3)0.77Mortality---no. (%\[95% CI\]) At day 606 (13)39 (12)0.73Creatinine at ICU discharge183.6 ± 136.4177.9 ± 150.10.81*ACEi* angiotensin-converting enzyme inhibitors, *ARB* angiotensin receptor blockers, *ICU* intensive care unit, *IQR* interquartile range, *RRT* renal replacement therapy, *CI* confidence intervalTable 2Multivariate analysisVariableOR95%CI*p*Age1.02\[1.00--1.05\]0.04MacCabe3.10\[1.64--5.87\]\< 0.001SAPS31.04\[1.02--1.07\]\< 0.01CKD1.99\[0.77--4.89\]0.14Congestive heart failure2.12\[0.66--6.43\]0.19History of acute stroke1.91\[0.80--4.38\]0.13ACEi/ARB at ICU discharge1.71\[0.71--3.90\]0.21*CKD* chronic kidney disease

We acknowledge that our study did not assess introduction nor interruption of ACEi/ARB after ICU discharge. One consequence of the severity of AKI in our study is that most patients had not fully recovered at ICU discharge. In this condition, physicians in charge could be reluctant to initiate ACEi/ARB in ICU but treated the patients later.

Our study does not confirm findings from two recent studies \[[@CR3], [@CR4]\]. This discrepancy could be explained by a different population (less severe AKI in previous studies) and/or a lack of power of our study but in any case warrant the performance of a randomized controlled trial of ACEi/ARB at ICU discharge after an episode of severe AKI.

ACEIs

:   Angiotensin-converting enzyme inhibitors

AKI

:   Acute kidney injury

ARBs

:   Angiotensin receptor blockers

ICU

:   Intensive care unit

KDIGO

:   Kidney Disease Improving Global Outcomes

RAS

:   Renin-angiotensin system

We thank patients and their surrogates who participated to AKIKI trial. We thank all medical and nurses teams from all study sites of AKIKI.

Funding {#FPar1}
=======

This study was supported by a grant from the Programme Hospitalier de Recherche Clinique National, 2012 (AOM12456), funded by the French Ministry of Health.

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

SG, DD, and MS conceived the study. AO and KC managed the data. AO performed the statistical analysis. SG, MS, and AO drafted the manuscript. All authors contributed substantially to the revision. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

The original trial was approved by the ethical committee of the French Society of Intensive Care Medicine and by the competent French legal authority (Comité de Protection des Personnesd'Ile de France VI, ID RCB 2013-A00765-40, NCT01932190) for all participating centers. According to French law, because the treatments and strategies used in the study were classified as standard care, there was no requirement for signed consent, but the patients or next of kin were informed about the study before enrolment and confirmed this fact in writing.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
